PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 17, 2026PharmaceuticalsOpen Access

UHPLC–Q–Orbitrap–HRMS-Based Multilayer Mapping of the Pharmacodynamic Substance Basis and Mechanistic Landscape of Maizibizi Wan in Chronic Nonbacterial Prostatitis Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaimaitiming MaihemutiMNM. NuermaimaitiWMWuermaitihan Maimaitiming

Discussion

Loading...

Member takes

Overview

This analysis uncovers the pharmacodynamic effects of Maizibizi Wan on chronic nonbacterial prostatitis, suggesting potential clinical applications.

Key Points

  • The study aims to elucidate the pharmacodynamic substance basis and mechanisms of Maizibizi Wan in treating chronic nonbacterial prostatitis.
  • Utilized UHPLC-Q-Orbitrap-HRMS for profiling MZBZ constituents and metabolites from rat plasma.
  • Employed network pharmacology to predict core targets and pathways.
  • Validated interactions using molecular docking techniques.
  • Conducted in vivo experiments on a λ-carrageenan-induced CNBP rat model with various assays including histopathology and cytokine analysis.
  • Identified 188 chemical constituents in MZBZ, including flavonoids, organic acids, and alkaloids.
  • Discovered 35 blood-absorbable components that involve Phase I and Phase II metabolic processes.
  • Found 54 core targets related to NF-κB and PI3K/AKT signaling pathways.
  • MZBZ treatment reduced inflammatory cytokines (TNF-α, IL-1β, IL-6) and altered signaling proteins in prostate tissue.

Cite This Study

Maihemuti et al. (2026) studied this question.

synapsesocial.com/papers/696b2696d2a12237a9349ddchttps://doi.org/10.3390/ph19010153
View Full Paper
Ask AI
Bookmark
Share